专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240084102A1 BISDIAMINOPHENYL COMPOUND, CROSSLINKING AGENT, COMPOSITION, AND MOLDED ARTICLE 审中-公开
公开(公告)号：US20240084102A1
公开(公告)日：2024-03-14
申请号：US18495426
申请日：2023-10-26
申请人： DAIKIN INDUSTRIES, LTD.
发明人： Tadashi KANBARA , Tsuyoshi NOGUCHI , Fumihiro KAMIYA , Daisuke OTA , Atsushi SUDO
IPC分类号： C08K5/34 , C07D213/60 , C07D215/44 , C07D241/20 , C07D241/54 , C07D251/42 , C08L27/12
CPC分类号： C08K5/34 , C07D213/60 , C07D215/44 , C07D241/20 , C07D241/54 , C07D251/42 , C08L27/12
摘要： A compound for use as a cross-linking agent represented by the following formula (1) wherein R1 is —SO2—, —O—, —CO—, an optionally substituted alkylene group, a group represented by the following formula (2) or a single bond; and two As are each independently an aromatic ring group containing a 5- or 6-membered aromatic ring and optionally containing a substituent, where the aromatic ring group contains a substituent in the case where the aromatic ring group is a monocyclic aromatic ring group containing a 6-membered aromatic hydrocarbon ring. Also disclosed is a composition containing the cross-linking agent.

2. 发明申请

US20150376198A1 MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL 审中-公开
标题翻译：血管紧张素受体与治疗潜力的调节剂
公开(公告)号：US20150376198A1
公开(公告)日：2015-12-31
申请号：US14768735
申请日：2014-02-18
申请人： THE SCRIPPS RESEARCH INSTITUTE
发明人： Edward Roberts , Gopi Kumar Mittapalli , Yuanhua Wang , Jun Yang , Marion Toussaint , Olga Habarova , Hugh Rosen
IPC分类号： C07D491/107 , C07D307/14 , C07D213/74 , C07D401/04 , C07D413/06 , C07D267/20 , C07D241/54 , C07D519/00 , C07D498/10 , C07D295/20 , C07D239/42
CPC分类号： C07D491/107 , C07D207/16 , C07D211/62 , C07D213/74 , C07D235/30 , C07D239/42 , C07D239/94 , C07D241/44 , C07D241/54 , C07D249/08 , C07D263/58 , C07D267/20 , C07D277/82 , C07D295/20 , C07D295/205 , C07D307/14 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/06 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/14 , C07D498/10 , C07D519/00
摘要： Compounds comprising piperazines, piperidines, spiro-furanopiperidines, and analogs thereof are provided that are modulators, such as positive allosteric modulators, of one or more subclasses of vasopressin receptors. The compounds can be selective modulators of one or more subclasses of vasopressin receptors. Compounds of the invention can be used in the treatment of a condition wherein modulating a vasopressin receptor is medically indicated for treatment of the condition.
摘要翻译：提供了包含哌嗪，哌啶，螺 - 呋喃丙哌啶及其类似物的化合物，其是一种或多种加压素受体亚类的调节剂，例如正变构调节剂。该化合物可以是一种或多种加压素受体亚类的选择性调节剂。本发明的化合物可用于治疗其中调节血管升压素受体在医学上指示用于治疗该病症的病症。

3. 发明申请

US20120232272A1 PROCESS FOR PRODUCING v-COELENTERAZINE COMPOUNDS 有权
标题翻译：生产伏安康唑化合物的方法
公开(公告)号：US20120232272A1
公开(公告)日：2012-09-13
申请号：US13412682
申请日：2012-03-06
申请人： Satoshi INOUYE , Yuiko Miura , Suguru Yoshida , Takamitsu Hosoya
发明人： Satoshi INOUYE , Yuiko Miura , Suguru Yoshida , Takamitsu Hosoya
IPC分类号： C07D487/04 , C07D241/38
CPC分类号： C07D241/38 , C07D241/20 , C07D241/44 , C07D241/54 , C07D487/04 , Y02P20/55
摘要： A simple process for producing v-coelenterazine compounds has been desired. Described is a process for producing a v-coelenterazine compound represented by general formula (II) comprising (1) the step of reacting a compound of general formula (VIII) with a methyltriphenylphosphonium salt in the presence of a base to give a compound represented by general formula (IX), (2) the step of performing a ring-closing metathesis reaction on any one selected from the group consisting of the compound represented by general formula (IX) and a compound of general formula (X) which is the compound of general formula (IX) wherein the amino is protected with R5, and then deprotecting R4 and, if any, R5 to give a v-coelenteramine compound represented by general formula (XIV), and (3) the step of reacting the compound of general formula (XIV) with a compound represented by general formula (XV) to give the compound of general formula (II).
摘要翻译：已经需要制备v-肠溶纤维素化合物的简单方法。本发明描述了一种制备由通式（II）表示的β-环糊精化合物的方法，包括（1）在碱存在下使通式（Ⅷ）化合物与甲基三苯基鏻盐反应，得到由通式（IX），（2）对选自由通式（IX）表示的化合物和作为化合物的通式（X）的化合物的任何一种进行闭环复分解反应的步骤的通式（IX）的化合物，其中氨基被R 5保护，然后使R 4和（如果有的话）R 5脱保护，得到由通式（XIV）表示的v-内网络胺化合物，和（3）通式（XIV）与通式（XV）表示的化合物反应，得到通式（II）的化合物。

4. 发明申请

US20080234276A1 Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors 审中-公开
标题翻译：杂环三嗪作为缺氧选择性蛋白激酶抑制剂
公开(公告)号：US20080234276A1
公开(公告)日：2008-09-25
申请号：US11815159
申请日：2006-02-01
申请人： Robert George Boyle , Stuart Travers
发明人： Robert George Boyle , Stuart Travers
IPC分类号： A61K31/53 , C07D253/10 , C12N9/99 , A61P35/00
CPC分类号： C07D239/76 , C07D215/48 , C07D215/60 , C07D239/94 , C07D241/20 , C07D241/54 , C07D253/07 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D471/04 , C07D487/04
摘要： The invention relates to novel heterocyclic triazines which are useful as hypoxic selective cytotoxic agents that mediate and/or inhibit cell proliferation, for example, through the activity of protein kinases. The invention is further related to pharmaceutical compositions containing such compounds and compositions, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation by administering effective amounts of such compounds.
摘要翻译：本发明涉及新的杂环三嗪，其可用作介导和/或抑制细胞增殖的缺氧选择性细胞毒性剂，例如通过蛋白激酶的活性。本发明进一步涉及含有这些化合物和组合物的药物组合物，以及通过施用有效量的这种化合物治疗癌症以及与不想要的血管发生和/或细胞增殖相关的其它疾病状态的方法。

5. 发明申请

US20030144284A1 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases 失效
公开(公告)号：US20030144284A1
公开(公告)日：2003-07-31
申请号：US10357240
申请日：2003-02-03
发明人： Michael R. Myers , Alfred P. Spada , Paul E. Persons , Martin P. Maguire
IPC分类号： A61K031/538 , A61K031/498 , C07D265/36 , C07D241/36
CPC分类号： C07D215/38 , C07D215/20 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12
摘要： This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

6. 发明授权

US06528526B1 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases 失效
公开(公告)号：US06528526B1
公开(公告)日：2003-03-04
申请号：US09675746
申请日：2000-09-29
申请人： Michael R. Myers , Wei He , Alfred P. Spada , Martin P. Maguire
发明人： Michael R. Myers , Wei He , Alfred P. Spada , Martin P. Maguire
IPC分类号： A61K3133
CPC分类号： C07D215/38 , C07D215/20 , C07D241/42 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12 , C07D453/06
摘要： This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

7. 发明授权

US5773439A Amido-quinoxalinediones, the preparation and use thereof 失效
标题翻译：酰胺 - 喹喔啉，其制备和用途
公开(公告)号：US5773439A
公开(公告)日：1998-06-30
申请号：US765260
申请日：1996-12-20
申请人： Wilfried Lubisch , Berthold Behl , Hans Peter Hofmann
发明人： Wilfried Lubisch , Berthold Behl , Hans Peter Hofmann
IPC分类号： C07D241/44 , A61K31/495 , A61P25/00 , A61P25/08 , A61P25/24 , A61P25/26 , C07D20060101 , C07D241/54 , C07D403/04 , C07D403/12
CPC分类号： C07D403/04 , C07D241/54
摘要： Novel amido-quinoxalinediones of the formula ##STR1## where R.sup.1 -R.sup.5, n and m have the meanings stated in the description, and the preparation thereof are described. The compounds are suitable for controlling diseases.
摘要翻译： PCT No.PCT / EP95 / 02324 371日期1996年12月20日第 102（e）日期1996年12月20日PCT提交1995年6月16日PCT公布。公开号WO95 / 35289 日期：1995年12月28日新颖的式（Ⅰ）所示的酰胺基喹喔啉，其中R1-R5，n和m具有说明书中所述的含义及其制备。该化合物适用于控制疾病。

8. 发明授权

US5620979A Glycine receptor antagonists and the use thereof 失效
标题翻译：甘氨酸受体拮抗剂及其用途
公开(公告)号：US5620979A
公开(公告)日：1997-04-15
申请号：US405708
申请日：1995-03-17
申请人： Eckard Weber , John F. W. Keana
发明人： Eckard Weber , John F. W. Keana
IPC分类号： C07D241/44 , A61K20060101 , A61K31/495 , A61K31/498 , A61K45/00 , A61K51/04 , A61P9/00 , A61P9/10 , A61P25/00 , A61P25/08 , A61P25/18 , A61P25/22 , A61P25/28 , C07D241/38 , C07D241/52 , C07D241/54 , C07D487/04 , C07D491/04
CPC分类号： C07D491/04 , A61K31/495 , A61K51/0459 , C07D241/38 , C07D241/44 , C07D241/52 , C07D241/54 , C07D487/04
摘要： Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal.Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.
摘要翻译：治疗或预防与中风，缺血，CNS创伤，低血糖和手术相关的神经元损失以及治疗神经变性疾病包括阿尔茨海默病，肌萎缩性侧索硬化，亨廷顿病和唐氏综合征的治疗或预防方法，治疗或预防多动症的不良后果通过向需要这种治疗的动物施用兴奋性氨基酸以及治疗焦虑症，慢性疼痛，惊厥，诱导麻醉和治疗精神病，通过向甘氨酸结合位点具有高亲和力的化合物，缺乏PCP副作用和哪些穿过动物的血脑屏障。还公开了新的1,4-二氢喹喔啉-2,3-二酮及其药物组合物。还公开了1,4-二氢喹喔啉-2,3-二酮的高度可溶性铵盐。

9. 发明申请

US20150031679A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK 有权
公开(公告)号：US20150031679A1
公开(公告)日：2015-01-29
申请号：US14499981
申请日：2014-09-29
申请人： BioEnergenix, LLC
发明人： John M. McCall , Donna L. Romero , John McKearn , Michael Clare
IPC分类号： C07D241/44 , C07D401/12 , C07D413/04 , C07D401/04 , C07D405/14 , C07D471/04 , C07D409/04 , C07D403/12 , C07D405/04
CPC分类号： C07D241/44 , A61K45/06 , C07D241/54 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/04 , C07D413/04 , C07D471/04
摘要： Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

10. 发明授权

US08916560B2 Heterocyclic compounds for the inhibition of PASK 有权
标题翻译：用于抑制PASK的杂环化合物
公开(公告)号：US08916560B2
公开(公告)日：2014-12-23
申请号：US13408893
申请日：2012-02-29
申请人： John M. McCall , John McKearn , Donna L. Romero , Michael Clare
发明人： John M. McCall , John McKearn , Donna L. Romero , Michael Clare
IPC分类号： A61K31/50 , A61K31/495 , C07D241/36 , C07D241/54 , A61K45/06 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/04 , C07D409/04
CPC分类号： C07D241/44 , A61K45/06 , C07D241/54 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/04 , C07D413/04 , C07D471/04
摘要： Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
摘要翻译：本文公开了新的杂环化合物和组合物及其作为用于治疗疾病的药物的应用。还提供了抑制人或动物受试者中PAS激酶（PASK）活性的方法用于治疗糖尿病等疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式